We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Astellas Signs $21.3 Million Deal With PeptiDream for Protein Degrader Cancer Treatment
Astellas Signs $21.3 Million Deal With PeptiDream for Protein Degrader Cancer Treatment
Astellas Pharma announced a $21.3 million research collaboration with PeptiDream to discover novel protein degraders — enzymes that disassemble and break down unneeded proteins — used in cancer treatments.
